Adam C. Resnick, PhD

PNOC Scientific Director

Dr. Adam Resnick is a pediatric neuro‑oncology research scientist at Children’s Hospital of Philadelphia (CHOP). He is the Director of CHOP’s Center for Data‑Driven Discovery in Biomedicine (D3b) and serves as the Scientific Director of the Children’s Brain Tumor Network (CBTN), as well as the Scientific Director of PNOC.

A leading voice in research-driven pediatric neuro-oncology and precision medicine, Dr. Resnick champions a future where open science, AI-powered platforms, and global collaboration radically transform outcomes for children with brain tumors. Dr. Resnick’s vision helped shape CBTN and PNOC’s data-driven ecosystem, now powering thousands of researchers worldwide. His work combines science and infrastructure, driving a research model where discovery is accelerated by access and every dataset is used to its fullest potential.

Education

Education

  • BS, University of Florida (Neuroscience), 1998

  • BA, University of Florida (English and Literature), 1999

  • PhD, Johns Hopkins School of Medicine (Neuroscience), 2006

Titles

Titles and Academic Titles

  • Director, Center for Data-Driven Discovery in Biomedicine (D3b)

  • Director, Neurosurgical Translational Research, Division of Neurosurgery

  • Scientific Chair, Children's Brain Tumor Tissue Consortium (CBTTC)

  • Scientific Chair, Pediatric Neuro-Oncology Consortium (PNOC)

  • Alexander B. Wheeler Endowed Chair in Neurosurgical Research

Awards

Awards & Recognition

  • Foerderer Award for Excellence, 2008

  • Howard Temin Pathway to Independence Award in Cancer Research, 2008

Research & Publications

Selected Research & Clinical Publications

  • Resnick AC, Kazerooni AF, Jiang Z, et al. Multi-Institutional Annotated Multiparametric MRI Dataset of Pediatric High-Grade Gliomas. Radiol Artif Intell. 2026;8(3):e250902. doi:10.1148/ryai.250902, Available from: https://pubmed.ncbi.nlm.nih.gov/42053414/

  • Resnick AC, Chrysochoou D, Gandhi DB, et al. AI-powered segmentation and prognosis with missing MRI in pediatric brain tumors. NPJ Precis Oncol. 2026;10(1):63. Published 2026 Jan 13. doi:10.1038/s41698-025-01269-x, Available from: https://pubmed.ncbi.nlm.nih.gov/41530498/

  • Resnick AC, Mackay A, Burford A, et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell. 2017;32(4):520-537.e5. doi:10.1016/j.ccell.2017.08.017, Available from: https://pubmed.ncbi.nlm.nih.gov/28966033/

  • Resnick AC, Kline C, Jain P, et al. Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003. Clin Cancer Res. 2022;28(18):3965-3978. doi:10.1158/1078-0432.CCR-22-0803, Available from: https://pubmed.ncbi.nlm.nih.gov/35852795/

  • Resnick AC, Vaske OM, Bjork I, et al. Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer. JAMA Netw Open. 2019;2(10):e1913968. Published 2019 Oct 2. doi:10.1001/jamanetworkopen.2019.13968, Available from: https://pubmed.ncbi.nlm.nih.gov/31651965/

  • Resnick AC, Jennifer L Stundon, Heba Ijaz, et al. Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants, Neuro-Oncology, Volume 25, Issue 7, July 2023, Pages 1331–1342, Available from: https://doi.org/10.1093/neuonc/noac278

For a complete list of published work:

https://pubmed.ncbi.nlm.nih.gov